Avance

Avance takes valuation a step further. Our combination of financial and industry expertise ensures your success in licensing, M&A, investing, and fund raising.

[Avance @AvanceBasel]

Be aware of the trap when doing your forecasting! This Graphic Explains 20 Cognitive Biases: https://t.co/FVq0FoduEW via @lifehacker

[Avance @AvanceBasel]

Meet us #BIOEUROPE in Cologne now! @i_demeter is looking forward seeing you there!

[Every Book @EveryBookBot]

A book about finance: Valuation in Life Sciences by Boris Bogdan & Ralph Villiger (2008)

[FiercePharma @FiercePharma]

Brexit means EMA must find a new home, and so much more https://t.co/wXxDNvqFfi #pharma by @EricPFierce

[AstraZeneca @AstraZeneca]

An estimated 152,000 women die each year from #ovariancancer. Learn more about the disease on #WOCD

[Madeleine Armstrong @ByMadeleineA]

Not all pharma cos are like $VRX - some invest in R&D (full story coming later via @EPVantage) HT @ByJonGardner

[Avance @AvanceBasel]

A #DNA Sequencer in Every Pocket. Sounds fascinating! https://t.co/tpAknWrJRR
#nextXmasPresent via @TheAtlantic

[Avance @AvanceBasel]

Working on our next newsletter. Topic: #forecasting. What`s your approach for a good forecast? #lifescience #sales #future

[Avance @AvanceBasel]

Patent Term for Rivaroxaban Extended in US until 2024. #bayer #patent #xarelto #US https://t.co/sIhYn3fl2Q

[Bristol Myers Squibb @bmsnews]

Bancroft: PD-1 is most prescribed drug for new patients in #NSCLC, strong adoption in renal cell carcinoma. $BMY

[Avance @AvanceBasel]

If you cannot value it, you cannot decide! https://t.co/Ixlm0fuExC #earlystage #biotech #valuation #pharma

[Avance @AvanceBasel]

Wondered how licensing agreements are structured even though little information is disclosed in PR? https://t.co/fpW7s0sREu #deals #pharma

[Avance @AvanceBasel]

Meet us at the #BioEuropeSpring in #Stockholm! @EBDgroup looking forward to the interesting program! #BES16 #BIO #valuation #lifesciences

[Iringó Demeter @i_demeter]

Representing @AvanceBasel at the #BioEurope Spring in #Stockholm next week. #BES16

[Avance @AvanceBasel]

Currency Effects - Often we model global sales simply as a rough figure, typically in USD. Maybe we say... http://t.co/1eSKgEcUKQ

[Avance @AvanceBasel]

Black's Risk-Free Discounting Rule - The discount rate – or the cost of capital – is the most influential... http://t.co/Lvbmi05YJx

[Avance @AvanceBasel]

rNPV vs. NPV - Modern forecast-based valuation methods are almost exclusively some sort of discounted cash... http://t.co/BQ0tyHUa6N

[Avance @AvanceBasel]

Early-Stage Valuation Myths - "Early stage projects always have a negative NPV” Everybody might have heard... http://t.co/2VLrnpB82w

[Avance @AvanceBasel]

Option Agreements - Over the past 5 years license contracts that include some options have become more... http://t.co/v2Zh2866Wu

[Avance @AvanceBasel]

Phase 2a/b Probabilities - Success rates vs. transition probabilities At the very beginning we need to... http://t.co/0RXW4LQXeb